Gestational diabetes is a type of diabetes that can develop during pregnancy in women who don’t already have diabetes. Gestational diabetes occurs when your body can’t make enough insulin during your pregnancy. Insulin is a hormone made by your pancreas that acts like a key to let blood sugar into the cells in your body for use as energy.
Diabetes is impacting the large group of people across the globe. There is noticeable increase in patients suffering from diabetes and mortality due to high sugar level. There is increase in number of pregnancy cases each day, with the chancing consumption pattern there is significant impact on the pregnancy. Gestational diabetes usually happens in the second half of pregnancy. It is a condition in which the blood sugar levels of the pregnant women become high for specific period of time. According to U.S. Department of Health & Human Services every year, 2% to 10% of pregnancies in the United States are affected by gestational diabetes. In this condition the mother’s body is not able to make and use all the insulin it needs for pregnancy. This condition leads to hyperglycemia where the glucose starts to build in blood. Rising cases of gestational diabetes across the globe and increasing awareness among consumers pertaining to availability of enhanced mediations are major factors expected to drive the growth of global gestational diabetes treatment market. Government in collaboration with public players is focused on R&D activities in order to deliver enhanced care to patients, coupled with increasing clinical trial by pharmaceutical companies are factors expected to support the growth of target market. In 2019, U.S. Food and Drug Administration approved the “Rybelsus” the first pill in a class of drugs called glucagon-like peptide (GLP-1). Rybelsus acts by slowing digestion and preventing the liver from making too much sugar, which helps the pancreas, produce more insulin.
Increasing government initiatives in order to increase the awareness among consumers related to gestational diabetes and introduction of health projects in order to treat the problems is expected to augment the growth of gestational diabetes treatment market. In 2016, Union ministry of health and family welfare has released guidelines on Gestational Diabetes Mellitus (GDM). As per the announcement they are waiting for the implementation of GDM management in the public sector. The roll-out of the programme will happen in a district in Madhya Pradesh. Players approach towards enhancing the business in developing countries in order to increase the customer base and increase the revenue share is expected to boost the growth of target market. Factors such as stringent government regulations related to drugs approval and high cost associated to drug development are expected to hamper the growth of global gestational diabetes treatment market. In addition, lack of awareness among consumers is expected to challenge the growth of target market. However, increasing investment by major players for development of new treatment drugs and increasing government spending on development of healthcare infrastructure are factors expected to create new opportunities for players operating in the gestational diabetes treatment market. In addition, increasing partnerships and agreements between regional and international players is expected to support the revenue transaction of the target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global gestational diabetes treatment market due to rise in number of cases related to complicate pregnancy. Favorable reimbursement policies by the government and introduction of novel treatments by major players operating in the country are factors expected to support the gestational diabetes treatment market regional growth. In addition, increasing merger & partnership activities in order to enhance the customer base and revenue share is responsible for the positive impact on the market.
The market in Asia Pacific is expected to witness faster growth in the target market due to low awareness among consumers. In addition, increasing obesity, delayed pregnancies, and rise in screening for gestational diabetes during prenatal testing are factors expected to impact the gestational diabetes treatment market growth.
The global gestational diabetes treatment market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Gestational Diabetes Treatment Market Segment Analysis, 2019
The global gestational diabetes treatment market is segmented into drug class, mode of administration, and distribution channel. The drug class segment is divided in to insulin, alpha-glucosidase inhibitors, SGLT-2 inhibitors, and others. The distribution channel segment is bifurcated into hospital pharmacies, retail pharmacies, and others. The players profiled in the report are Biocon Limited, Eli Lilly and Company, Novo Nordisk, Boehringer Ingelheim GmbH, Sanofi S.A., Sun Pharmaceutical Industries Limited, Merck & Co., Inc., Novartis International AG, and Adocia.
Market By Drug Class
Market By Mode of Administration
Rising cases of gestational diabetes across the globe and increasing awareness among consumers pertaining to availability of enhanced mediations are major factors expected to drive the growth of global gestational diabetes treatment market.
In drug class the insulin segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Eli Lilly and Company, Novo Nordisk, Boehringer Ingelheim GmbH, and Sanofi S.A
The North America is expected to account for major revenue share in the global market.
In distribution channel the cancer hospital pharmacies segment is growing at faster pace.
Factors such as stringent government regulations related to drugs approval and high cost associated to drug development are expected to hamper the growth of global gestational diabetes treatment market.